针对细胞质NPM1突变区域的免疫反应可能有助于NPM1突变（NPM1mut）的急性髓系白血病患者获得良好的临床结果。 - Suppr

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

作者信息

Greiner Jochen, Schneider Vanessa, Schmitt Michael, Götz Marlies, Döhner Konstanze, Wiesneth Markus, Döhner Hartmut, Hofmann Susanne

出版信息

Blood. 2013 Aug 8;122(6):1087-8. doi: 10.1182/blood-2013-04-496844.

DOI:10.1182/blood-2013-04-496844

PMID:23929838

Abstract

摘要

相似文献

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).针对细胞质NPM1突变区域的免疫反应可能有助于NPM1突变（NPM1mut）的急性髓系白血病患者获得良好的临床结果。

Blood. 2013 Aug 8;122(6):1087-8. doi: 10.1182/blood-2013-04-496844.

Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.核仁磷酸蛋白 1 的突变区域在急性髓系白血病患者中引发 CD4(+)和 CD8(+)T 细胞反应。

Blood. 2012 Aug 9;120(6):1282-9. doi: 10.1182/blood-2011-11-394395. Epub 2012 May 16.

Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.NPM1突变和FLT3内部串联重复在埃及细胞遗传学正常的急性髓系白血病患者中的预后意义

Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25.

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.新抗原特异性 T 细胞免疫反应：NPM1 突变型急性髓系白血病的范例。

Int J Mol Sci. 2021 Aug 25;22(17):9159. doi: 10.3390/ijms22179159.

Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.供体淋巴细胞输注在伴有NPM1突变的急性髓系白血病中诱导多特异性CD8(+) T细胞反应并同时实现分子缓解。

J Clin Oncol. 2013 Jan 20;31(3):e44-7. doi: 10.1200/JCO.2011.41.1116. Epub 2012 Dec 17.

Autologous T cells on the attack against AML.自体 T 细胞攻击 AML。

Blood. 2012 Aug 9;120(6):1151-2. doi: 10.1182/blood-2012-06-433177.

Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.核型正常的急性髓系白血病患者中非 A 型 NPM1 和 FLT3 突变的临床意义。

Acta Haematol. 2012;127(2):63-71. doi: 10.1159/000331509. Epub 2011 Nov 18.

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.与 A/D 型核磷蛋白突变相关的 HLA I 类分子谱改变提示急性髓系白血病中可能存在抗核磷蛋白免疫反应。

PLoS One. 2015 May 20;10(5):e0127637. doi: 10.1371/journal.pone.0127637. eCollection 2015.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.NPM1 突变型急性髓系白血病患者的异基因造血干细胞移植：来自 SAL-AML 2003 试验中前瞻性 HLA 配型后供者与无供者分析的结果。

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29.

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.突变核仁磷酸蛋白 1 作为急性髓系白血病的免疫治疗靶点。

J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14.

引用本文的文献

The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response.急性髓系白血病常见基因突变与免疫格局之间的相互作用：免疫反应的机制及意义

Front Immunol. 2025 Aug 11;16:1635111. doi: 10.3389/fimmu.2025.1635111. eCollection 2025.

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.新型Menin-KMT2A抑制剂JNJ-75276617（即Bleximenib）可损害急性髓系白血病的长期增殖和免疫逃逸能力。

Haematologica. 2025 Jun 1;110(6):1278-1291. doi: 10.3324/haematol.2024.285616. Epub 2024 Dec 19.

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.突变型核仁磷酸蛋白1在急性髓系白血病治疗中的免疫治疗潜力

Cancers (Basel). 2024 Oct 10;16(20):3443. doi: 10.3390/cancers16203443.

Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.异基因造血干细胞移植后复发的急性髓系白血病的细胞治疗

Biomedicines. 2024 Aug 1;12(8):1721. doi: 10.3390/biomedicines12081721.

Frameshift Mutations in Leukemia-Associated Genes Correlate With Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia.白血病相关基因中的移码突变与接受异基因干细胞移植治疗急性髓系白血病患者的较好预后相关。

J Hematol. 2024 Jun;13(3):86-93. doi: 10.14740/jh1276. Epub 2024 Jun 28.

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.NPM1 突变型 AML 的诊断和分子监测标准。

Blood Cancer Discov. 2024 Jan 8;5(1):8-20. doi: 10.1158/2643-3230.BCD-23-0144.

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1) for the Treatment of NPM1-Acute Myeloid Leukemia.基于针对突变型核磷蛋白（NPM1）的细胞毒性T淋巴细胞的先进治疗药物用于治疗NPM1急性髓系白血病的临床前验证

Cancers (Basel). 2023 May 12;15(10):2731. doi: 10.3390/cancers15102731.

Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.基于新抗原特异性TCR-T细胞的急性髓系白血病免疫疗法。

Exp Hematol Oncol. 2022 Nov 16;11(1):100. doi: 10.1186/s40164-022-00353-3.

Targeted therapy in NPM1-mutated AML: Knowns and unknowns.NPM1 突变型急性髓系白血病的靶向治疗：已知与未知

Front Oncol. 2022 Sep 27;12:972606. doi: 10.3389/fonc.2022.972606. eCollection 2022.

Current status and future perspectives in targeted therapy of NPM1-mutated AML.NPM1 突变型 AML 的靶向治疗的现状与展望。

Leukemia. 2022 Oct;36(10):2351-2367. doi: 10.1038/s41375-022-01666-2. Epub 2022 Aug 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献